Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug

Provention Bio entered a co-promotion agreement with Sanofi Thursday ahead of the possible November approval of Type 1 Diabetes drug teplizumab.

If approved, teplizumab would be the first drug approved to modify T1D. Under terms of the deal, pending FDA approval, Sanofi and Provention will co-promote teplizumab in the United States.